​FDA Approvals

Sign up to get the latest information on cancer research and AACR events!

*By clicking Sign Up Now you agree to our terms and read our privacy policy.

 

 

Targeting Several Blood Cancers669The FDA has approved a new molecularly targeted therapeutic called duvelisib for treating certain patients with blood cancer.11/19/2018 5:14:49 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031L_FDAapp_BloodCancer_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Several Blood CancersThe FDA has approved a new molecularly targeted therapeutic called duvelisib for treating certain patients with blood cancer.80
New Immunotherapeutic Approved for Common Skin Cancer949The FDA decision makes cemiplimab-rwlc the first-ever treatment approved specifically for treating squamous cell carcinoma.11/16/2018 7:00:34 PM15https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031M_FDAapp_Immuno_SquamousCell_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />New Immunotherapeutic Approved for Common Skin CancerThe FDA decision makes cemiplimab-rwlc the first-ever treatment approved specifically for treating squamous cell carcinoma.79
Expanding Immunotherapy to Small Cell Lung Cancer790The FDA has expanded the use of the immunotherapeutic nivolumab to treat certain patients with small cell lung cancer.11/15/2018 9:24:08 PM13https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031G_FDAapp_Immuno_SmallCell_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Expanding Immunotherapy to Small Cell Lung CancerThe FDA has expanded the use of the immunotherapeutic nivolumab to treat certain patients with small cell lung cancer.78
A New Type of Targeted Therapy for Leukemia163The FDA has approved the first of a new type of molecularly targeted therapy for use in treating certain patients with a rare type of leukemia.11/15/2018 8:50:15 PM22https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031H_FDAapp_Leukemia_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Type of Targeted Therapy for LeukemiaThe FDA has approved the first of a new type of molecularly targeted therapy for use in treating certain patients with a rare type of leukemia.77
First Immunotherapeutic for Rare Types of Non-Hodgkin Lymphoma2773The FDA has approved a new immunotherapeutic for treating two types of cutaneous T-cell lymphoma, mycosis fungoides and Sézary syndrome.11/8/2018 8:16:03 PM62https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031C_FDAapp_NHL_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />First Immunotherapeutic for Rare Types of Non-Hodgkin LymphomaThe FDA has approved a new immunotherapeutic for treating two types of cutaneous T-cell lymphoma, mycosis fungoides and Sézary syndrome.73
A New Targeted Therapy Combination for Melanoma1382The FDA has approved a third combination of targeted therapeutics for treating patients who have metastatic melanoma with certain gene mutations.11/5/2018 3:36:42 PM170https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031E_FDAapp_Melanoma_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Targeted Therapy Combination for MelanomaThe FDA has approved a third combination of targeted therapeutics for treating patients who have metastatic melanoma with certain gene mutations.70
Increasing Liver Cancer Treatment Options1637The FDA has approved expanding the use of lenvatinib to treat certain patients with the most common type of liver cancer.11/13/2018 6:35:46 PM54https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031I_FDAapp_LiverCancer_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Increasing Liver Cancer Treatment OptionsThe FDA has approved expanding the use of lenvatinib to treat certain patients with the most common type of liver cancer.76
Combining Targeted Therapy and Immunotherapy for Non-Hodgkin Lymphoma6266The FDA has approved the combination of ibrutinib and rituximab as a new treatment for a rare form of non-Hodgkin lymphoma.11/12/2018 3:22:16 PM70https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031J_FDAapp_Walden_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Combining Targeted Therapy and Immunotherapy for Non-Hodgkin LymphomaThe FDA has approved the combination of ibrutinib and rituximab as a new treatment for a rare form of non-Hodgkin lymphoma.75
Expanding Immunotherapy to Cervical Cancer1911The FDA has expanded the use of the immunotherapeutic pembrolizumab to treat certain patients with cervical cancer.8/6/2018 1:50:19 PM595https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1801021M_Cervical_150x190_1.jpg" style="BORDER&#58;0px solid;" />Expanding Immunotherapy to Cervical CancerThe FDA has expanded the use of the immunotherapeutic pembrolizumab to treat certain patients with cervical cancer.68
A New Immunotherapeutic for Non-Hodgkin Lymphoma325The FDA has expanded the use of pembrolizumab to treat certain patients with non-Hodgkin lymphoma.8/1/2018 2:21:55 PM276https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1801021N_pembrolizumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Immunotherapeutic for Non-Hodgkin LymphomaThe FDA has expanded the use of pembrolizumab to treat certain patients with non-Hodgkin lymphoma.67

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300